Mostrar el registro sencillo

dc.contributor.authorReal de Asua, Diegoes_ES
dc.contributor.authorMayer, Miguel A.es_ES
dc.contributor.authorOrtega, María del Carmenes_ES
dc.contributor.authorBorrel, Jose M.es_ES
dc.contributor.authorBermejo, Teresa de Jesúses_ES
dc.contributor.authorGonzález-Lamuño Leguina, Domingo es_ES
dc.contributor.authorManso, Corales_ES
dc.contributor.authorMoldenhauer, Fernandoes_ES
dc.contributor.authorCarmona-Iragui, Maríaes_ES
dc.contributor.authorHüls, Ankees_ES
dc.contributor.authorSherman, Stephanie L.es_ES
dc.contributor.authorStrydom, Andrees_ES
dc.contributor.authorTorre, Rafael de laes_ES
dc.contributor.authorDierssen, Maraes_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2022-04-19T14:22:44Z
dc.date.available2022-04-19T14:22:44Z
dc.date.issued2021-08-23es_ES
dc.identifier.issn2077-0383es_ES
dc.identifier.urihttp://hdl.handle.net/10902/24605
dc.description.abstractWhether the increased risk for coronavirus disease 2019 (COVID-19) hospitalization and death observed in Down syndrome (DS) are disease specific or also occur in individuals with DS and non-COVID-19 pneumonias is unknown. This retrospective cohort study compared COVID-19 cases in persons with DS hospitalized in Spain reported to the Trisomy 21 Research Society COVID-19 survey (n = 86) with admissions for non-COVID-19 pneumonias from a retrospective clinical database of the Spanish Ministry of Health (n = 2832 patients). In-hospital mortality rates were significantly higher for COVID-19 patients (26.7% vs. 9.4%), especially among individuals over 40 and patients with obesity, dementia, and/or epilepsy. The mean length of stay of deceased patients with COVID-19 was significantly shorter than in those with non-COVID-19 pneumonias. The rate of admission to an ICU in patients with DS and COVID-19 (4.3%) was significantly lower than that reported for the general population with COVID-19. Our findings confirm that acute SARS-CoV-2 infection leads to higher mortality than non-COVID-19 pneumonias in individuals with DS, especially among adults over 40 and those with specific comorbidities. However, differences in access to respiratory support might also account for some of the heightened mortality of individuals with DS with COVID-19.es_ES
dc.description.sponsorshipFunding: The lab of M.D. is supported by the Departament d’Universitats, Recerca i Societat de la Informació de la Generalitat de Catalunya (Grups consolidats 2017 SGR 926, 2017 SGR 138). We also acknowledge the support of the Agencia Estatal de Investigación (PID2019-110755RBI00/AEI/10.13039/501100011033), the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848077, Jerôme Lejeune Foundation (No 2002), NIH (Grant Number: 1R01EB 028159-01), Marató TV3 (#2016/20-30), JPND Heroes project. CRG acknowledges the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. The CIBER of Rare Diseases (CIBERER) and CIBER of Physiopathology of Obesity and Nutrition (CIBEROBN) are initiatives of the ISCIII. D.R.A. is partially supported by the Fondo de Investigaciones Sanitarias (FIS grant PI19/00634, European Fund for Regional Development—EFRD) and the Foundation Jérôme Lejeune (grant no. 1777-2018). The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), funded by ISCIII and EDER (PT17/0009/0014). The DCEXS is a ‘Unidad de Excelencia María de Maeztu’, funded by the AEI (CEX2018-000782-M). The GRIB is also supported by the Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya (2017 SGR 00519). AH was supported by the HERCULES Center (NIEHS P30ES019776) and by the LuMind IDSC Foundation. Acknowledgments: The study was supported by Down Syndrome Affiliates in Action, Down Syndrome Medical Interest Group-USA, GiGi’s Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, National Down Syndrome Society, and National Task Group on Intellectual Disabilities and Dementia Practices.es_ES
dc.format.extent11 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAttribution-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nd/4.0/*
dc.sourceJournal of clinical medicine 2021, 10, 3748es_ES
dc.titleComparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndromees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.3390/jcm10163748es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOIdoi.org/10.3390/jcm10163748es_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution-NoDerivatives 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NoDerivatives 4.0 International